Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Pfizer's Setback in Duchenne Muscular Dystrophy Treatment Trial Clears Path for…
According to DelveInsight's estimates, the US accounted for around ~17K total prevalent cases of Duchenne muscular dystrophy in 2023. The highest cases were found in the children of the 5-9 age group, these numbers are expected to grow by the year 2034. According to DelveInsight's estimates, the US accounted for around~17Ktotal prevalent cases of Duchenne muscular dystrophy in 2023. The highest cases were found in the children of the5-9 age group, these numbers are expected to grow by...
PR Newswire
17/06/2024
RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC which is an…
MANHATTAN BEACH, Calif., June 17, 2024 /PRNewswire/ -- On 24 May 2024, Meridian Bidco LLC ("Bidco") made an offer to acquire the entire issued and to be issued share capital of MariaDB plc ("MariaDB") (the "Offer") with the terms and conditions of the Offer set out in the offer document despatched and filed by Bidco as Exhibit (a)(1)(A) to the Tender Offer Statement filed on Schedule TO with the US Securities and Exchange Commission on 24 May 2024 (the "Offer…
PR Newswire
17/06/2024
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+®…
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH 1in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). The...
Nasdaq GlobeNewswire
17/06/2024
Global Omega-3 Pet Supplement Sales Set to total USD 2,292.5 million by 2034…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19711 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19711 The humanization of pets drives the global omega-3 pet supplement industry forward. People want good health for their pets. Pet owners purchase supplements to ensure their pets receive the proper nutrition and...
PR Newswire
17/06/2024
The era of biosolutions. Outlook upgraded for 2024
Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%. Novonesis' Capital Markets Day on June 18, 2024 will provide an introduction to Novonesis with insights on how the company intends to capture and accelerate organic sales growth. Also, Novonesis maintains the target for organic sales growth at 6-8% CAGR through 2025 with an adjusted...
Nasdaq GlobeNewswire
17/06/2024
Surgical Suction Instruments Market to Hit USD 503 Million by 2029, Driven by…
Browse in-depth TOC on "Surgical Suction Instruments Market" Browse in-depth TOC on "Surgical Suction Instruments Market" 390 - Tables 300 - Figures400 - Pages Surge in Surgical Procedures Fuels Demand for Suction Instruments The escalating number of surgeries globally serves as a prime catalyst for the surgical suction instruments market. With surgeries on the rise, the demand for these vital tools intensifies, ensuring optimal surgical conditions, minimizing...
PR Newswire
17/06/2024
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine…
First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and olderRepresents first BLA for a chikungunya vaccine for adolescentsCOPENHAGEN, Denmark, June 17, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. Food and Drug Administration (FDA) for a Biologics License...
Nasdaq GlobeNewswire
17/06/2024
Dental 3D Printing Materials Market to be Worth $5.4 Billion by 2031 - Exclusive…
Dental laboratories use 3D printers to produce crowns and bridges, orthodontic models, surgical guides, aligners, castable restorations, and others. As the manual model-making process is time-consuming, 3D printing allows multiple products to be printed simultaneously with higher accuracy. Dental laboratories use 3D printers to produce crowns and bridges, orthodontic models, surgical guides, aligners, castable restorations, and others. As the manual model-making process is time-consuming, 3D...
PR Newswire
17/06/2024
Membrane Chromatography Market to Reach USD 637 Million with 14.7% CAGR |…
Browse in-depth TOC on "Membrane Chromatography Market"416 - Tables52 - Figures348 - Pages Browse in-depth TOC on "Membrane Chromatography Market" 416 - Tables 52 - Figures 348 - Pages DRIVER: Catalyzing Growth Through Increased Biopharmaceutical R&D As C-level executives, you're aware of the pivotal role R&D plays in the biopharmaceutical sector, especially amidst the escalating demand for treatments targeting chronic illnesses. The robust increase in R&D...
PR Newswire
17/06/2024
Renowned Public Health Expert Prof. Siegal Sadetzki Joins Briya
With Prof. Sadetzki joining the Briya team and helping design data cleansing and medical evaluation processes, life science companies can be assured that the data they receive is of the highest quality, providing a comprehensive view of the patient journey. This enables them to expedite research timelines, obtain more accurate results, allocate resources more efficiently for clinical studies, and develop data-driven market strategies. With Prof. Sadetzki joining the Briya team and helping...
PR Newswire
17/06/2024
PRADA SPRING/SUMMER 2025 MENSWEAR SHOW
To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9275551-prada-spring-summer-2025-menswear-show/ To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9275551-prada-spring-summer-2025-menswear-show/ **FACE** Alexander enhances skin with Prada Skincare, employing Prada Augmented Skin The Essence as a first step. This transformative 2-in-1 toner and micro-peel essence optimizes and renews skin texture while gently...
PR Newswire
17/06/2024
CardioFlow's VitaFlow Liberty™ Granted EU CE-MDR Mark, Advancing Global…
CardioFlow, one of the world's leading innovative medical device companies, has entered the field of structural heart disease when the field was still at an early adoption phase. Originating and headquartered in Shanghai, China, CardioFlow was listed on the Hong Kong Stock Exchange on February 2021. The company has a diverse product pipeline resulting from independent and collaborative research, covering structural heart devices such as transcatheter aortic, mitral, and tricuspid valves, left…
PR Newswire
17/06/2024
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 10, 2024, to June 14, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
17/06/2024
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of…
The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumor microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors. The license includes 5 new patent families that were just filed...
PR Newswire
17/06/2024
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug…
“With the initiation of the first Phase 3 study for belrestotug, we are entering a monumental stage in our journey to develop a world-leading oncology company. Nearly 70% of patients with first-line PD-L1 high non-small cell lung cancer rely upon a chemotherapy-free regimen. We believe belrestotug + dostarlimab are poised to potentially advance the therapeutic regimen in this setting and establish new benchmarks,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos...
Nasdaq GlobeNewswire
17/06/2024
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® –…
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June17, 2024(GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that with first doses in Austria administered in May 2024, it is making strong progress in the European roll-out of PYLCLARI ®(INN: Piflufolastat ( 18 F) also known as ( 18 F)-DCFPyL) indicated for the detection of prostate-specific membrane...
Nasdaq GlobeNewswire
17/06/2024
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic…
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion's personalized cancer vaccine, EVX-01, in patients with metastatic melanomaThe findings also demonstrate strong and clinically relevant immune responses after EVX-01 administration to metastatic melanoma patients co-treated with anti-PD-1 standard of care The clinical study results substantiate the precision and predictive power of Evaxion's AI-Immunology™...
Nasdaq GlobeNewswire
17/06/2024
PartitionBio™ awarded grant to exploit its novel biologics shuttle platform for…
PartitionBio™ is a Cambridge (UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of macromolecules with therapeutic potential across the cell membrane. Possible payloads for the shuttle condensates include antibodies, proteins, peptides and nucleic acids. PartitionBio ™ is aCambridge(UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of...
PR Newswire
17/06/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
17/06/2024
Children's Tumor Foundation Presents the 2024 Global NF Conference in Brussels…
NF, encompassing neurofibromatosis type 1 (NF1), and all forms of schwannomatosis (SWN), including NF2-related schwannomatosis (NF2-SWN), affects approximately 4 million people worldwide. These genetic conditions cause tumors to grow on nerves throughout the body, leading to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer. The Global NF Conference aims to redefine the future of NF research and care, accelerating the path to effective…
PR Newswire
17/06/2024
Multiple New Awards Recognize NCCN as Exceptional Source for Information for…
PLYMOUTH MEETING, Pa., June 17, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced new recognitions for the award-winning library of NCCN Guidelines for Patients® and NCCN Patient Webinars. The NCCN Guidelines for Patients: Colon Cancer earned a Gold Award from Hemes Creative Awards for Electronic Media/Social Media/Interactive Media/Digital Publications/Messaging. The NCCN Guidelines for Patients: Kidney Cancer earned an Award of Distinction from The…
PR Newswire
17/06/2024
Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US…
Lenire is the first bimodal neuromodulation device to receive a Federal Supply Schedule (FSS) Contract. It can be prescribed when appropriate by a trained healthcare clinician for the treatment of tinnitus. Lenire is the first bimodal neuromodulation device to receive a Federal Supply Schedule (FSS) Contract. It can be prescribed when appropriate by a trained healthcare clinician for the treatment of tinnitus. General Services Administration's decision to award the FSS contract was based on...
PR Newswire
17/06/2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for…
“We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment,” said Paul Moore, Chief Scientific Officer of Zymeworks. “ZW171's unique design is intended to address the limitations of current bispecific T-cell engagers by enhancing tumor selectivity and improving safety. With promising preclinical results, ZW171 has the potential to provide a more effective and tolerable treatment option for patients with...
Nasdaq GlobeNewswire
17/06/2024
ZINZINO AB (PUBL): LETTER OF INTENT TO ACQUIRE ZURVITA INCREASES DISTRIBUTION…
The business has total annual sales of approximately USD 30 million with good gross margins. The collaboration with Zinzino is expected to add growth through the synergies that arise in the joint networks, combined with Zinzino's test-based product concept. The profitability of the Company will thus be able to develop well by utilizing Zinzino's existing technical platform and organization. The business has total annual sales of approximatelyUSD 30 millionwith good gross margins. The...
PR Newswire
17/06/2024
Altri Comunicati
